| |
Newsroom /
Science and Research
/
Science and Research
/
Peripheral Ulcerative Keratitis Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Peripheral Ulcerative Keratitis Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Peripheral Ulcerative Keratitis Therapeutics Market is forecast to Show Slow Growth to 2017, The report identifies the key trends shaping and driving the global PUK market.
Hyderabad,
AP,
India
(prbd.net)
15/06/2011
GlobalData valued the global Peripheral Ulcerative Keratitis (PUK) therapeutics market at $418m in 2010
and forecast it to grow at a Compound Annual Growth Rate (CAGR) of 7.4% to reach $690m by 2017.
This growth is primarily attributed to the expected increase in the general population. The increased use
of contact lenses will also lead to a marginal increase in infectious PUK.
The PUK therapeutics market has high unmet needs because there are no approved drugs for treatment.
This implies that the market is only moderately served by the current products, which leaves wide scope
for the launch of new technology and products that can capture the market. Corticosteroids,
immunosuppressants and biologics are the currently available therapeutic options. An approved product
with enhanced efficacy and safety is likely to achieve blockbuster status, with the potential to capture a
significant share of the market.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Trigeminal-Neuralgia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
There are currently no molecules under clinical development in the PUK therapeutics market. This
indicates that pharmaceutical companies are not focused on the research and development of new
therapies for PUK. This primarily attributed to a complex etiology and pathophysiology of PUK as it
involves different causative factors as well as different mechanistic pathways which lead to the
development of PUK. A complex pathophysiology represents a challenging clinical development
environment and may not be favorable to the development of a single drug which can block multiple
pathophysiologic pathways and ultimately present a cure for the disease.
GlobalData, the industry analysis specialist, has released its new report, “Peripheral Ulcerative Keratitis
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global peripheral ulcerative keratitis (PUK) market. The report identifies the key trends shaping and driving the global PUK market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the
pipeline products within the global PUK sector. This report is built using data and information sourced
from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Trigeminal-Neuralgia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|